What is CAGR? What does CAGR table indicate for Nectar Lifesciences Ltd?

Compounded average growth rate (CAGR) measures the average annual growth rate compounded year-on-year over a period of time.

Nectar Lifesciences Ltd Stock Analysis

Q: Is Nectar Lifesciences Ltd a good quality company?

MoneyWorks4Me analysed the past 10-year performance of Nectar Lifesciences Ltd and arrived at the following conclusion.

Small Cap

Evaluated by 1569 users | BSE: 532649 | NSE: NECLIFE |
Pharmaceuticals & Drugs

Nectar Lifesciences (NecLife) incorporated in 1995, is a $200 million pharmaceutical organization. The company offers a range of Cephalosporin active pharmaceutical ingredients (APIs) and finished dosage forms. The company was previously known as Surya Medicare and is is promoted by Sanjiv...

10 Year X-Ray

Standalone basis Standalone basis P Consolidated basis P

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

What is a Financial Track Record? How to read this chart in order to understand the data present here?

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20
Return on Capital Employed	11.48%	9.25%	9.32%	8.98%	8.4%	7.41%	7.18%	6.81%	7.52%	6.02%

Growth Parameters	Growth Parameters Colour Code Guide

Net Sales (Rs. Cr.)	1,062	1,313	1,626	1,638	1,644	1,676	1,643	1,876	2,785	2,363
Y-o-Y Gr. Rt.	-	23.6%	23.9%	0.7%	0.3%	2%	-2%	14.1%	48.5%	-15.2%
Adjusted EPS (Rs.)	4.7	3.3	3.82	2.77	2.95	2.43	2.42	2.33	2.12	1.33
Y-o-Y Gr. Rt.	-	-29.8%	15.8%	-27.5%	6.5%	-17.6%	-0.4%	-3.7%	-9%	-37.3%
Book Value per Share (Rs.)	32.16	34.98	38.69	41.34	41.11	42.55	44.89	47.21	49.26	50.59
Adjusted Net Profit	105	74.1	85.7	62.1	66.2	54.4	54.3	52.2	47.5	29.9
Net Op. Cash Flow (Rs. Cr.)	44	165	361	255	144	169	199	65.1	239	286
Debt to Cash Flow from Ops	18.1	6.32	2.44	3.37	6.4	5.7	4.42	14.66	3.78	2.73

Difference between Standalone Basis and Consolidated basis? Which method is preferred for Nectar Lifesciences Ltd. ?

Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.

Nectar Lifesciences Ltd. should be analysed on a Standalone basis

CAGR CAGR Colour Code Guide

	9 yrs	5 yrs	3 yrs	1 yr
Net Sales	9.3%	7.5%	12.9%	-15.2%
Adjusted EPS	-13.1%	-14.7%	-18.1%	-37.3%
Book Value per Share	5.2	4.2	4.1	2.7
Share Price	3.6%	-4.5%	8%	115.7%

Key Financial Parameter	Performance Ratio Colour Code Guide

	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20
Return on Equity (%)	15.7	9.84	10.37	6.92	7.02	5.69	5.54	5.05	4.39	2.67
Operating Profit Margin (%)	21.56	19.02	17.84	17.57	16.24	14.26	13.64	12.59	9.48	9.23
Net Profit Margin (%)	9.92	5.64	5.27	3.79	4.03	3.25	3.3	2.78	1.71	1.26
Debt to Equity	1.1	1.33	1.01	0.93	1	1.01	0.87	0.9	0.82	0.69
Working Capital Days	276	276	251	270	285	298	324	292	206	240
Cash Conversion Cycle	172	172	133	125	134	142	153	133	104	115

Management X-Ray

Shareholding Pattern

Entity	Percentage Holding
Promoters	55.80%
Institutions	2.62%
Non-Institutions	41.58%

Promoter's Holding & Share Pledging

Pledged ^*

55.85

0.00

* Pledged shares as % of Promoter's holding (%)

FAQs

1. Is Nectar Lifesciences Ltd a good quality company?

Data is not available for this company.

2. Is current market price of Nectar Lifesciences Ltd a good price to buy it?

The 5-year analysis of Nectar Lifesciences Ltd's performance infers:

Nectar Lifesciences Ltd earnings have declined by -14.7%, whereas share price has depreciated -4.5% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

3. What is Nectar Lifesciences Ltd share price return in the past 10 years ?

We analysed the performance of Nectar Lifesciences Ltd share prices over the last 10 years. Here is what we found out:

Nectar Lifesciences Ltd share price has depreciated 1.5% annually over the past ten years.

About Company

NecLife is among few Indian manufacturers to develop, manufacture and market Oral and Sterile Cephalosporins and Semi Synthetic Penicillins. The company is amongst the few life saving API

NecLife is among few Indian manufacturers to develop, manufacture and market Oral and Sterile Cephalosporins and Semi Synthetic Penicillins. The company is amongst the few life saving API manufacturing companies that produces sterile APIs, through both Lyophilization and Crystallization processes.

Headquartered in Chandigarh, the company's manufacturing facilities are located at Derabassi (API and Menthol), Baddi (FDF and EHGC) and Jammu (Menthol). The company's marketing offices are situated at Delhi, Mumbai and Indore.

NecLife has received two star â€˜Export Houseâ€™ status from the Government of India. The company has received ISO 9001:2000 certification for quality management. The companyâ€™s manufacturing facilities for APIs were developed as per USFDA /EDQM guidelines. These facilities have also been certified by WHO GMP. The company also has a well equipped R&D unit that focuses on development of new molecules.

NecLifeâ€™s products have export presence in over 45 countries spread across 5 continents.

Products

NecLife manufactures and markets APIs namely Cephalothin Sodium, Cefazolin Sodium, Flucloxacillin Sodium, Oxacillin Sodium, Sulbactum Sodium, Azithromycin Dihydrate, Ceftazidime, Meropenem, Cefdinir are many others.
Among under finished dosage, the company manufactures products in different forms such as tablets, capsules, dry syrup and injectables (vials). It manufactures products such as Cefadroxil, Cefprozil, Cephalexin, Cefaclor and many more.
NecLife undertakes complete range of contract research and manufacturing services which includes formulation development, lyophilization cycle development, labelling and packaging, QC testing, stability studies and regulatory support.
NecLife manufactures two-piece double lock gelatin capsules under GMP standards and ISO 9002 guidelines. These capsules are BSE (Bovine spongiform encephalopathy)-free and contain no sulfites has shelf life of 5 years.
NecLife has also ventured into Phyto-chemicals with launch of â€œNECTAR MENTHOLâ€ offering Menthol and derived products.

Future Plans

Besides India, Nectar Lifesciences plans to explore the untapped markets in regions namely Russia and CIS, China, Asia and USA.

Read Less